HuidaGene Biotechnology Co., Ltd (辉大基因) is a global biotechnology company focusing on CRISPR-based genetic medicine to rewrite the future of genomic medicine.
Shanghai & New Jersey
Joined November 2022
- Tweets46
- Following30
- Followers93
- Likes58
HuidaGene Therapeutics retweeted
Folks: $RCKT news has almost no read-through to any other AAV9 (or any other capsid serotype) programs, in any disease, in any organ, for any Sponsor not doing high dose systemic.
High doses administered systemically carry risks. Full stop.
Low doses + local admin = the way
HuidaGene Therapeutics retweeted
I discuss the urgent crisis from the loss of federal support of science in the US and recent clinical gene editing breakthroughs with @WalterIsaacson & @amanpour on @AmanpourCoPBS, airing on @PBS tonight at 11 pm ET, and on @cnni earlier today. Pls share!
youtube.com/watch?v=8YhJM6zx…
Honored our #DMD all-in-one AAV #CRISPR #hfCas12Max was selected for #ASGCT2025 Presidential talk presented by @AlvinLuk_Health.HG302 Highlights at Low Dose:
-0.5% on-target DNA editing
-3.9% productive RNA editing (Day90),>22-fold gain from Day0
–NSAA/mobility gains +55m in 6MWT
Congratulations to @AlvinLuk_Health on being named to the #TIME100Health list — honoring the most 100 influential global leaders transforming the #future of #health.
At @HuidaGene , we don’t just pursue #innovation —we pursue cures.
TIME's new cover: Meet this year's #TIME100Health, a community of leaders—scientists, doctors, advocates, educators, and policy-makers, among others—who are changing the health of the world. ti.me/43802LZ
May is #ALSAwarenessMonth.
#ALS affects patients and their loved ones. At @HuidaGene, we’re developing HG303 — a one-time #CRISPR- #hfCas12Max therapy to knock down #ATXN2 and halt TDP-43 aggregation.
ALS is relentless. So are we.
#GeneEditing #GeneTherapy #HuidaGene #ALS
Breaking barriers at #ASGCT2025:
✔ 13 abstracts
✔ 5 oral talks
✔ 1 Presidential Symposium
#DNA. #RNA. #AI.
Programmable medicine starts here. See you in New Orleans, @ASGCTherapy !
#GeneTherapy #CRISPR #BiotechInnovation #ProgrammableMedicine #GeneEditing #ASGCT25 #ASGCT
In this Year of Snake,we reflect on the 🐍 symbolism of #wisdom, #transformation, and #innovation, resonating our mission.We embrace challenges with #creativity and determination, transforming #CRISPR #GeneEditing technologies into life-changing treatments for patients worldwide.
Time is #muscle for #Duchenne #musculardystrophy #patients. Delighted to announce our HG302 #CRISPR /Cas12 DNA-editing therapy for DMD was granted rare pediatric disease designation as the world's first CRISPR/Cas12 #geneediting for DMD by the US FDA.
prnewswire.com/news-releases…
Going to SF for the #BiotechShowcase on Jan 8-10, 2024, organized by @EBDgroup? Want to know more about the #future of #CRISPR #geneediting with our #novel tools and pipelines in #blindness, #maculardegneration, and #CNS, schedule a meeting with us through @InformaConnect !
We're excited to share the progress of our ophthalmology program at 2o Congreso Europeo Pacientes Mácula Retina by @macularetina , bringing hopes to patients suffering from #blindness or #visual #disabilities .
#ceguera #discapacidad #biotecnologia #genetherapy #genomicmedicines
We are looking forward to the @Jefferies #London #healthcare Conference tomorrow. Read our press release for additional details.
#JefferiesHealthcare #Jefferies #GeneEditing #GeneTherapy #investors #biotech #healthcare #medicine
Attending #BIOEurope Fall 2023 of @IAmBiotech by @EBDgroup from 6-8 November in #Münich, #Germany ? Are you interested in discussing transformative genome #medicine for potential #partnerships ?
Let’s talk and see you there!
#biotechnology #technology #collaboration #innovation
A big thank you to our first patient with #inherited #retinaldisease caused by #RPE65 mutations! HG004 has already validated its safety and efficacy in children & adults using different AAV than LUXTURNA. Stay tune for our impressive data soon. #RareDisease #blind #GeneTherapy
HG004 for RPE65-IRD is the Company's first program receiving both #orphandrug designation (ODD) and #rare #pediatric disease designation (RPDD) by the U.S. FDA. Company's HG204 for #MECP2 duplication syndrome is the second program receiving both #odd and #RPDD recently.
A big thank you to our MDS team for pioneering the development of HG204 (#CRISPR #RNA -#GeneEditing therapy for MDS) and communicating with @US_FDA , without whom none of this would've been possible. We look forward to bringing HG204 into clinic soon. #RareDisease #neuroscience
Excited to announce last patient has been dosed in our LIGHT trial evaluating HG004 #genetherapy for #LCA. HG004 has granted both orphan drug and rare pediatric disease designations by US FDA. #blindness #RareDisease #rare #biotechnology #pharmaceuticals #medicine #ophthalmology
Dr. Yang @Yanglab9 orally presented a new class of base-editor at @ESGCT ! The team (@Huawei_Tong & @yingsi28551665) published in @NSR_Family of a deaminase-free base editor.#GeneEditing #genetherapy #ESGCT #CRISPR #biotechnology #innovation #medicine #technology #pharmaceuticals
We are here in Brussels, Belgium for @ESGCT 30th Annual Congress (#ESGCT2023 ) and are excited to share 13 poster and oral presentations on our progress of #CRISPR #GeneEditing and #GeneTherapy #pipeline. Check out out our 13 presentations here!!
